Navigation Links
Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
Date:3/17/2008

Potential to Develop Disease Treatments for Diabetic Kidney Disease and

Retinopathy, Each Multi-Billion-Dollar Drug Markets

JENKINTOWN, Pa., March 17 /PRNewswire/ -- Dynamis Therapeutics, Inc. announced the discovery of a new class of compounds that inhibit the production of RAGE, the Receptor for Advanced Glycation End Products (AGEs). Scientists expect that a RAGE inhibitor would be an important addition to the arsenal of drugs to treat diabetic kidney disease, retinopathy, microvascular disease, Alzheimer's, inflammatory diseases, some cancers, and aging.

A patent has been filed on the discovery.

A team of Dynamis Therapeutics' scientists significantly decreased kidney and retina RAGE in aged rats that were orally dosed with Dynamis Therapeutics' RAGE inhibitor for 32 weeks, as compared to non-treated rats. In addition, several other new compounds also inhibited RAGE in a variety of cells grown in culture.

In a parallel experiment, Dynamis Therapeutics' scientists increased the life span of mice by adding a RAGE inhibitor to their drinking water. The laboratory mice were divided into four groups: a control group treated only with water and three groups treated with varying doses of the RAGE inhibitor. The mice receiving the highest RAGE inhibitor dose lived, on average, 256 days longer than those receiving only water. Longevity increased proportionally with dosage strength.

Commented Dr. Annette Tobia, president and founder of Dynamis Therapeutics, Inc., "We are very excited about these results, since discovering RAGE inhibitors enables Dynamis Therapeutics to develop a treatment for diabetic kidney disease and blindness. Diabetes and its complications have become epidemic, not only in the United States, but worldwide. Retinopathy often leads to blindness. It would be a tremendous advance to eventually have a drug to treat such a serious disease."

Dynamis Therapeutics, Inc., located in Jenkintown, Pennsylvania (http://www.dynamis-therapeutics.com), develops products that treat chronic inflammatory conditions and accelerated aging diseases such as diabetic nephropathy and retinopathy.

Dynamis Therapeutics supports its research, in part, by marketing the MEG 21 product line of anti-aging and anti-wrinkling cosmetic skin care products to dermatologists, plastic surgeons, and aestheticians and by out-licensing the cosmetic applications of its breakthrough technology for fees and royalties.

Dynamis Therapeutics' technology is based on the discovery of an aging/inflammatory pathway that was made by its scientific founders while they were working at the Fox Chase Cancer Center in Philadelphia. The technology is exclusively licensed to Dynamis Therapeutics. Dynamis Therapeutics is presently preparing to file an IND with the FDA for a treatment for inflammation associated with dry eye.


'/>"/>
SOURCE Dynamis Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
2. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
3. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
4. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
7. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
8. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
9. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
10. Video: New Research Discovers Independent Brain Networks Control Human Walking
11. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016  The Senior Care Pharmacy ... Reform Committee Chairman Jason Chaffetz (R-UT) ... today,s hearing , "Developments in the Prescription ... and growing questions about abusive pharmacy benefit manager ... (R-UT) and Ranking Member Elijah Cummings (D-MD) are ...
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot ... 2015 Best in KLAS: Software & Services for HIT Implementation Support & Staffing ... report independently ranks vendor performance by healthcare executives, managers and clinicians representing over ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... founder of CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda ... CitiDent offers a complete range of oral health care, including general dentistry, cosmetic ...
(Date:2/5/2016)... , ... February 05, 2016 , ... In sleep, when ... as a dream. A hallmark feature of patients with eating disorders is significant self-criticism, ... eating disorder behaviors and obsessions are regarded as maladaptive means for coping with this ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... manufactures practical mobile kitchens, recently announced the debut of their latest mobile kitchen ... Mobile Kitchens provides organizations with modern, high-volume commercial kitchens for use anywhere in ...
Breaking Medicine News(10 mins):